Cereno Scientific AB (publ) (FRA:4A1)

Market Cap	173.79M +11.2%
Revenue (ttm)	4.09M -45.3%
Net Income	-10.88M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	236
Open	0.5400
Previous Close	0.5460
Day's Range	0.5400 - 0.5400
52-Week Range	0.4990 - 1.1030
Beta	n/a
RSI	46.41
Earnings Date	May 11, 2026

About Cereno Scientific AB

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and anti-thrombotic properties. Its drugs portfolio ...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 10
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4A1

Financial Performance

In 2025, Cereno Scientific AB's revenue was 44.27 million, a decrease of -45.28% compared to the previous year's 80.90 million. Losses were -117.75 million, 18.3% more than in 2024.

Financial numbers in SEK